Key industry issues as we see them:
-
Defending challenges of patents and supplementary protection certificates for leading branded drugs and assisting companies in the launch of branded generics and other generic products.
-
Maximising the productivity of R&D and the strength of the product pipeline through strategic in-licensing and out-licensing.
-
Increasing focus on the biotech sector through acquisitions, such as J&J’s acquisition of Cougar Biotechnology, and new challenges facing this sector, such as the rise of biosimilars.
-
Growth of emerging marketswhere there are lower R&D costs and ever-increasing markets, particularly in China, India and Brazil
-
Significant structural change is expected over the next 10 years in response to social-economic factors (e.g. ageing population, increased wealth, focus on “wellness”/lifestyle rather than cure, growing numbers of obesity related diseases)
Examples of significant sector projects on which we have advised
